Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin HDL Kinetics in Metabolic Syndrome
NCT00240305Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2004
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of rosuvastatin in metabolic syndrome, dyslipidemia, sponsored by AstraZeneca. Started Apr 2004; status: completed.
02
Drugs
rosuvastatin
03
Conditions
metabolic syndromedyslipidemia
Beyond the preview
Go deeper on NCT00240305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00240305.